Trial of Vemurafenib and Cobimetinib in Patients With Advanced BRAFV600 Mutant Melanoma
- Registration Number
- NCT02427893
- Brief Summary
This trial explores the immunologic effects of vemurafenib (BRAF inhibitor) and cobimetinib (MEK inhibitor), administered alone and in combination, to patients with advanced BRAF V600E/K mutant melanoma.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- All
- Target Recruitment
- Not specified
- Signed informed consent
- Signed HIV testing consent
- Life expectancy ≥ 12 weeks
- Able to swallow pills
- ECOG performance status 2 or less
- Adequate bone marrow function
- Adequate renal function
- Adequate liver function
- Negative urine pregnancy test within 7 days prior to commencement of dosing in premenopausal women
- Histological diagnosis of unresectable AJCC stage III or stage IV, BRAFV600E/K mutant melanoma
- Measurable disease
- Accessible tumor that can be biopsied
- Naive to targeted therapy (Prior immune-based therapy in the adjuvant setting or for advanced disease will be allowed if >2 weeks from study entry)
-
Active systemic infection
-
Active autoimmune disease or history of known or suspected autoimmune disease
-
Active brain metastases or leptomeningeal metastases
-
Treatment with any immunomodulatory medication within 4 weeks of initiation of study therapy.
-
Positive test for hepatitis B virus
-
Positive test for hepatitis C virus
-
Positive test for human immunodeficiency virus (HIV)
-
Pregnant, lactating or breast feeding women
-
Localized radiation therapy within the last 14 days
-
History of malabsorption
-
No consumption of the following within 7 days prior to start of treatment:
- St. John's wort or hyperforin (potent cytochrome P450 CYP3A4 enzyme inducer)
- Grapefruit juice (potent cytochrome P450 CYP3A4 enzyme inhibitor
-
History or evidence of cardiovascular risk
-
History or evidence of retinal pathology
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Cohort 1 Cobimetinib Ten patients begin Vemurafenib monotherapy, after 10 days, begin combination therapy by adding Cobimetinib. Cohort 1 Vemurafenib Ten patients begin Vemurafenib monotherapy, after 10 days, begin combination therapy by adding Cobimetinib. Cohort 2 Cobimetinib Ten patients begin Cobimetinib monotherapy, after 10 days, begin combination therapy by adding Vemurafenib. Cohort 2 Vemurafenib Ten patients begin Cobimetinib monotherapy, after 10 days, begin combination therapy by adding Vemurafenib.
- Primary Outcome Measures
Name Time Method Safety and tolerability of cobimetinib monotherapy and combination vemurafenib/cobimetinib in subjects with advanced melanoma. 2 years compare immunologic changes described above with the development of study treatment-related adverse events. For example, severity or extent of rash from cobimetinib (a well-described dermatologic toxicity of MEK inhibitors) may be compared to levels of intratumoral immune activation assessed by one or more of the parameters.
- Secondary Outcome Measures
Name Time Method Anti-tumor activity of cobimetinib monotherapy and combination vemurafenib/cobimetinib in subjects with advanced melanoma. 2 years compare immunologic changes described above with therapeutic outcomes, including CR, PR, SD, and PD measured by RECIST 1.1. For example, tumor regression may be correlated with levels of intratumoral immune activation or expression of immune checkpoints assessed by one or more of the parameters
Trial Locations
- Locations (1)
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
🇺🇸Baltimore, Maryland, United States